We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+2.5%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$183M
AUM Growth
-$648M
Cap. Flow
-$649M
Cap. Flow %
-355.28%
Top 10 Hldgs %
95.28%
Holding
36
New
4
Increased
–
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
SRZN icon
Surrozen
SRZN
+$9.38M
2
OLK
Olink Holding AB (publ) American Depositary Shares
OLK
+$3.63M
3
ARYE
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
+$2.98M
4
SRZNW icon
Surrozen Inc Warrant
SRZNW
+$458K

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$155M
2
SWTX
SpringWorks Therapeutics
SWTX
+$68.8M
3
LEGN icon
Legend Biotech
LEGN
+$67.6M
4
VSTM icon
Verastem
VSTM
+$55.4M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$54.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.2%
2 Financials 7.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNDM icon
1
Tandem Diabetes Care
TNDM
$1.17B
$58.2M 31.84%
487,327
-491,899
-50% -$54.2M
GMED icon
2
Globus Medical
GMED
$10.4B
$45.1M 24.71%
589,100
-495,879
-46% -$39.8M
UTHR icon
3
United Therapeutics
UTHR
$26.3B
$29.1M 15.95%
157,838
-1,249
-0.8% -$246K
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$19.4M 10.63%
305,994
-893,345
-74% -$68.8M
SRZN icon
5
Surrozen
SRZN
$229M
$6.72M 3.68%
+66,667
New +$9.38M
SLN
6
Silence Therapeutics
SLN
$521M
$3.73M 2.04%
178,787
-43,435
-20% -$1.04M
ARYE
7
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$2.96M 1.62%
+300,000
New +$2.98M
RACB
8
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$2.96M 1.62%
300,000
– –
JYAC
9
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.93M 1.6%
300,000
– –
MSAC
10
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$2.92M 1.6%
300,000
– –
OLK
11
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$2.8M 1.53%
+115,425
New +$3.63M
PANA
12
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$1.95M 1.07%
200,000
– –
CASI
13
DELISTED
CASI Pharmaceuticals
CASI
$1.86M 1.02%
156,300
-875,896
-85% -$11.8M
MLTX icon
14
MoonLake Immunotherapeutics
MLTX
$1.59B
$1.49M 0.82%
150,000
– –
SRZNW icon
15
Surrozen Inc Warrant
SRZNW
$49.5K
$361K 0.2%
+333,333
New +$458K
CMAXW
16
DELISTED
CareMax, Inc. Warrant
CMAXW
$134K 0.07%
45,960
– –
MSACW
17
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$24K 0.01%
33,331
– –
ACET icon
18
Adicet Bio
ACET
$72.8M
– –
-64,088
Closed -$10.6M
AFMD
19
DELISTED
Affimed
AFMD
– –
-317,642
Closed -$27M
CLRB icon
20
Cellectar Biosciences
CLRB
$19.3M
– –
-13,043
Closed -$4.66M
KROS icon
21
Keros Therapeutics
KROS
$199M
– –
-887,885
Closed -$37.7M
LEGN icon
22
Legend Biotech
LEGN
$4.3B
– –
-1,647,497
Closed -$67.6M
NKTX icon
23
Nkarta
NKTX
$162M
– –
-439,876
Closed -$13.9M
PTGX icon
24
Protagonist Therapeutics
PTGX
$8.75B
– –
-3,446,874
Closed -$155M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.66B
– –
-409,301
Closed -$31.8M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Consonance Capital Management held 36 positions worth $183M, down 78% from $831M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Consonance Capital Management withdrew a net $649M in Q3 2021, closing 19 positions and reducing 6 holdings. Its most notable exit was Protagonist Therapeutics, an estimated $155M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials.

Against the trend, Consonance Capital Management opened a new position in Surrozen worth $6.72M.

  • Consonance Capital Management's largest Q3 2021 buy was Surrozen: 66,667 shares worth $6.72M.
  • Consonance Capital Management's biggest Q3 2021 reduction was SpringWorks Therapeutics, cutting an estimated $68.8M.
  • Consonance Capital Management fully exited Protagonist Therapeutics in Q3 2021, selling an estimated $155M.
  • Consonance Capital Management's ten largest holdings make up 95% of its $183M portfolio in Q3 2021.
  • Consonance Capital Management opened 4 new positions and closed 19 in Q3 2021.
  • Consonance Capital Management's portfolio value fell 78% quarter-over-quarter to $183M.

Based on Consonance Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.